单独针对胰腺癌细胞的靶向疗法已证实难以改善胰腺癌患者五年生存率，调控间质组织是最新倡导的发展方向，其核心理念是可控性递送化疗药及稳定间质组织动态平衡，未来研究以两者为焦点。课题组前期研发的超声靶向递送纳米技术在胰腺癌细胞及体内移植瘤上实现了药物富集、抑制率增强及可视化递送的效果，是一种诊疗一体化的靶向给药策略，有望为调控间质组织提供一种较为齐备的治疗模式。本课题拟制备包载吉西他滨Gem和维生素D类似物卡泊三淳Cal的纳米微囊，其表面修饰靶向识别胰腺间质组织骨膜蛋白Per的特异抗体；在靶向抗体的引导及超声辐照下有效促进复合纳米载体Peri-Gem-Cal进入胰腺癌间质组织，依据超声图像量化微囊来评估治疗前后胰腺癌间质成分的改变，从而进行调控性给药，利用卡铂三淳“静息”间质组织活跃的优势，使吉西他滨更好地发挥对胰腺癌细胞杀伤作用，从而最终实现提高化疗疗效延长患者生存期的效果。

It has been clearly proved that the adjuvant therapy of targeting pancreatic cancer cells cannot increase the five-year survival rate for pancreatic cancer patients. The newly developed regime of increasing the effect of adjuvant therapy in pancreatic cancer patients was regulating stromal compartments. The core idea of this strategy is not only controllable delivery of chemotherapy drugs but also balancing the pros and cons effect of stromal towards unto cancer cells. The domestic and international research nowadays in progress was focused on realizing both those ideas. In previous studies, the applicant research group had developed an advanced drug delivery system, which was mediated by coupling ultrasound and Nano-particles. This coupling method had achieved the effects of drug accumulation, tumor inhibition and visualized delivery under ultrasound in vitro and in vivo, and was regarded as an integration of diagnosis and treatment, which is expected to supply a comparatively well-equipped strategy in remodeling stromal compartment in pancreatic cancer patients. In this study, the applicant proposed to prepare a new multifunctional Nano-capsule, which includes the Gemcitabine (Gem) and Calcitrol (the analogues of Vitamin D which can “rest” the stromal) and was modified with Periostin on its surface. The Nano-capsule will be accumulated locally in pancreatic cancer stromal by the guidance of specific targeted antibody and the irradiation of ultrasound. The Nano-capsules will be visualized by ultrasound, and the changes of stromal elements will be estimated by quantification analysis, which will control the delivery process. Taking the advantage of Calcitrol in “resting” pancreatic stromal, the cell-killing effect of Gemcitabine will be increased, and the goal of extending the 5-year survival rate of pancreatic cancer patients is expected to be realized.